Exelixis, Inc.: Initiation Of Coverage – Does It Have A Sustainable Competitive Advantage?

Throughout 2023, Exelixis Inc, showed a strong overall performance with increased demand and revenue growth in its cabozantinib franchise, globally. As per their recent conference call, they revealed that the franchise’s net product revenues rose by 14% YoY in Q4 2023. The 2023 full-year revenue also grew by 16% YoY. Moreover, the global cabozantinib franchise net product revenues produced by Exelixis, and its partners reached approximately $2.3 billion in 2023. The company is now focusing on its 2024 financial forecasts to be revealed by the CFO, Chris Senner. Exelixis anticipates a ruling on the second MSN in the first half of 2024, which would be a significant milestone for the company.